Back to top
more

Insulet (PODD)

(Real Time Quote from BATS)

$320.31 USD

320.31
366,724

-11.82 (-3.56%)

Updated Sep 17, 2025 11:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System

by Zacks Equity Research

Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.

Zacks Equity Research

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Strength of the base business bodes well for Quest Diagnostics (DGX).

Zacks Equity Research

Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Insulet (PODD) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Boston Scientific's (BSX) FARAPULSE PFA System Gets FDA Nod

by Zacks Equity Research

Boston Scientific (BSX) secures FDA approval for the FARAPULSE PFA system.

Zacks Equity Research

Insulet (PODD) Gains From Product Innovation, Global Expansion

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.

Zacks Equity Research

Thermo Fisher (TMO) End Market Growth Strong Despite Macro Woes

by Zacks Equity Research

Thermo Fisher's (TMO) electron microscopy, chromatography and mass spectrometry businesses are delivering strong growth in the academic and government end market.

Zacks Equity Research

QIAGEN (QGEN) Forges Alliance to Advance Microbiome Sciences

by Zacks Equity Research

QIAGEN (QGEN) announces a first-in-kind collaboration with Penn State University to help shape research, education and outreach in microbiomes.

Zacks Equity Research

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.

Zacks Equity Research

Universal Health (UHS) Up 5.3% in 6 Months: More Room to Run?

by Zacks Equity Research

Universal Health's (UHS) rising patient volumes and better pricing position the company well for growth.

Zacks Equity Research

Here's Why Insulet (PODD) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Why Insulet (PODD) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Alcon (ALC) Business Hurt by Macroeconomic Woes, Competition

by Zacks Equity Research

In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.

Zacks Equity Research

Thermo Fisher (TMO) End Markets Drive Growth Amid Macro Woes

by Zacks Equity Research

In the academic and government end markets, Thermo Fisher (TMO) is delivering strong growth in the electron microscopy, chromatography and mass spectrometry businesses.

Zacks Equity Research

Here's Why You Should Retain Edward Lifesciences (EW) Stock Now

by Zacks Equity Research

Investors remain optimistic about Edward Lifesciences (EW) due to the strength of its product group.

Zacks Equity Research

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Medtronic's (MDT) expansion in global markets and stable solvency position.

Zacks Equity Research

Omnicell (OMCL) Gains From Innovation Amid Cost Pressure

by Zacks Equity Research

Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.

Zacks Equity Research

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors remain optimistic about Teleflex (TFX), backed by the strong prospects of the Interventional business and stable solvency.

Zacks Equity Research

Boston Scientific (BSX) Initiates AVANT GUARD Clinical Trial

by Zacks Equity Research

Boston Scientific's (BSX) AVANT GUARD clinical trial is set to evaluate the FARAPULSE PFA System as the first-line treatment for persistent AF.

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD)

by Zacks Equity Research

Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Globus Medical (GMED) Gains From Innovation Amid Macro Issues

by Zacks Equity Research

Globus Medical (GMED) is particularly seeing notable gains in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Zacks Equity Research

Walgreens (WBA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in U.S. Healthcare and International businesses is likely to drive Walgreens' (WBA) first-quarter 2024 performance.

Zacks Equity Research

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

by Zacks Equity Research

Investors remain optimistic about Labcorp (LH) due to impressive partnerships and expansion efforts in targeted high-growth areas.

Moumi Mondal headshot

5 Impressive MedTech Industry Growth Stocks to Buy for 2024

by Moumi Mondal

Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.

Zacks Equity Research

Here's Why You Should Invest in Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position.